title: The value and limitation of transcatheter arterial chemoembolization in preventing recurrence of resected hepatocellular carcinoma.
abstract: OBJECTIVE
  To evaluate the value and limitation of postoperative transcatheter arterial chemoembolization (TACE) in preventing recurrence of hepatocellular carcinoma (HCC).
  
  
  METHODS
  In the first group, 987 postoperative patients with HCC, who did not have any evidence of recurrence in the first preventative TACE but were found to have recurrence at different times during the follow-up survey, were analyzed. In the second group, 643 postoperative patients with HCC had no TACE for compared study. To study the relationship between the recurrence time and the number of TACE treatments was analyzed.
  
  
  RESULTS
  The 6-, 12-, and 18-mo recurrence rates in the first and second groups were 22.2% (210 cases) vs 61.6% (396 cases), 78.0% (770 cases) vs 74.7% (480 cases) and 88.6% (874 cases) vs 80.1% (515 cases). There were significant differences between the recurrence rates of the two groups at 6 mo (P<0.0001).
  
  
  CONCLUSIONS
  The principal role of TACE after HCC operation is to suppress, detect early and treat micro-metastasis. It has a good effect of preventing recurrence of HCC in 6 mo, but such an effect is less satisfactory in a longer period. When it is uncertain whether HCC is single-central or multi-central and if there is cancer residue or metastasis after operation, TACE is valuable to prevent recurrence.
authors.affiliation: Department of Radiology, Eastern Hepatobiliary Surgery Hospital, Shanghai 200438, China. chengys9304@yahoo.com.cn
authors.forename: Hong-Yan
authors.initials: HY
authors.lastname: Cheng
authors.forename: Xiang
authors.initials: X
authors.lastname: Wang
authors.forename: Dong
authors.initials: D
authors.lastname: Chen
authors.forename: Ai-Min
authors.initials: AM
authors.lastname: Xu
authors.forename: Yu-Chen
authors.initials: YC
authors.lastname: Jia
mesh_terms: D006528:Carcinoma, Hepatocellular / Q000473:pathology / Q000601:surgery / Q000628:therapy*; D016461:Chemoembolization, Therapeutic / Q000379:methods*; D006801:Humans; D008113:Liver Neoplasms / Q000473:pathology / Q000601:surgery / Q000628:therapy*; D009364:Neoplasm Recurrence, Local / Q000517:prevention & control*; D012189:Retrospective Studies; D013997:Time Factors; D016896:Treatment Outcome